Video Shorts

What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care
1:45
What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care
4 months ago
by
Amrita Krishan, MD
Maurie Markman, MD
1:20
Clinical Equipose When Recommending Individual Clinical Trials
4 months ago
by
Maurie Markman, MD
Marc L Greenwald, MD
1:22
Robotics, Cost, and Caution: What’s Actually Advancing Surgical Care in CRC?
4 months ago
by
Marc Lehrer Greenwald, MD
C. Ola Landgren, MD, PhD, discusses the importance of driving additional precision medicine approaches in the treatment of patients with multiple myeloma.
1:13
Precision Medicine Remains the Priority During Multiple Myeloma Awareness Month
4 months ago
by
C. Ola Landgren, MD, PhD
Jeremy Kortmansky, MD
1:22
Missed Signs and Screening Gaps: Why Is Early CRC Detection Falling Short?
4 months ago
by
Jeremy Kortmansky, MD
Georges Gebrael, MD, University of Utah
0:36
Elucidating the Next Steps After EV-Pembro in Urothelial Carcinoma
4 months ago
by
Georges Gebrael, MD
Marla D. Lipsyc-Sharf, MD
1:27
Exploring the Evolution of ctDNA Testing in Breast Cancer
4 months ago
by
Marla D. Lipsyc-Sharf, MD
Chris Labaki, MD, Dana-Farber Cancer Institute
0:22
PD-L1 As a Prognostic Biomarker in Penile Cancer
4 months ago
by
Chris Labaki, MD
Sami Diab, MD
0:46
Emphasizing the Importance of Considering Different Patient Priorities
4 months ago
by
Sami Diab, MD
Richard Kim, MD, Moffitt Cancer Center
0:56
Anal Cancer Care Is Entering a New Era of Precision Medicine and Immunotherapy Use
4 months ago
by
Richard Kim, MD
Sandip Patel, MD, Atlantic Health
1:41
Examining Results From the ENVISION Trial in NMIBC
5 months ago
by
Sandip M. Prasad, MD
Jorge Cortes, MD
1:29
Long-Term Goal-Based TKI Treatment Decision-Making for Patients With CML
5 months ago
by
Jorge Cortes, MD
Shubham Pant, MD, MBBS
1:00
Targeted Therapies Continue to Reshape Third-Line Treatment Sequencing Decisions in CRC
5 months ago
by
Shubham Pant, MD, MBBS
Wendy Stock, MD, discusses the goal of the 2026 ASH Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
0:30
ASH Guidelines Provide Key Recommendations in AYA ALL Management
5 months ago
by
Wendy Stock, MD
Laura Alder, MD
1:29
Local vs Systemic Therapy for CNS Metastases in Lung Cancer
5 months ago
by
Laura Alder, MD
Hung Khong, MD
0:39
Previewing Future Directions for Investigating RSK Inhibition in Breast Cancer
5 months ago
by
Hung T. Khong, MD
Utilizing MRD Status in Acute Lymphoblastic Leukemia Management
2:04
Utilizing MRD Status in Acute Lymphoblastic Leukemia Management
5 months ago
by
Jae Park, MD
Maurie Markman, MD
1:11
Of mice but not men. Problems of the randomized clinical trial
5 months ago
by
Maurie Markman, MD
David Wise MD
1:02
Examining Pasritamig Plus Docetaxel in mCRPC
5 months ago
by
David R. Wise, MD, PhD
Shubham Pant, MD, MBBS
0:56
Peptide Receptor Radionucleotide Therapies Gain Momentum in NETs
5 months ago
by
Shubham Pant, MD, MBBS
OncLive News Roundup for the Week of 3/8
3:48
OncLive News Roundup for the Week of 3/8
5 months ago
by
Chris Ryan(+1 more)
Maurie Markman, MD
1:25
Ethics and Identity in Oncology: Clinician vs Investigator
5 months ago
by
Maurie Markman, MD
MBCC 2026
1:29
Recapping Top Coverage from MBCC 2026!
5 months ago
by
Ashling Wahner (+1 more)
Rami Komrokji, MD, discusses treatment decision-making for patients with higher-risk myelodysplastic syndromes who experience progression following treatment with a hypomethylating agent–based regimen.
1:59
Navigating Treatment Selection After HMA Failure in Higher-Risk MDS
5 months ago
by
Rami S. Komrokji, MD
Tycel Phillips, MD
0:42
Navigating BTK Inhibitor Data for MCL and Important Next Steps for the Field
5 months ago
by
Tycel Phillips, MD
Javid Moslehi, MD
0:37
Spotlighting the Role of Cardio-Oncology in Breast Cancer Care
5 months ago
by
Javid Moslehi, MD
Alicia Morgans, MD, MPH
2:16
Unpacking Real-World Outcomes With ARP Inhibitor Therapy in mHSPC
5 months ago
by
Alicia Morgans, MD, MPH, FASCO
Research Areas of Interest in Frontline Lower-Risk MDS
1:07
Research Areas of Interest in Frontline Lower-Risk MDS
5 months ago
by
Jan Bewersdorf, MD, FACP
Neha Vapiwala, MD, FASTRO, FASCO, FACR
1:50
Inside the Most Notable Data in Prostate Cancer From ASCO GU 2026
5 months ago
by
Neha Vapiwala, MD, FASTRO, FASCO, FACR
Is Early-Onset CRC a Biologically Distinct Disease? Drs Marshall and Lieu Explore the Evidence
1:20
Is Early-Onset CRC a Biologically Distinct Disease? Drs Marshall and Lieu Explore the Evidence
5 months ago
by
Courtney Flaherty